Increased body fat mass reduces the association between fructosamine and HbA1c in obese type 2 diabetic patients.
Fiche publication
Date publication
août 2020
Journal
Journal of diabetes investigation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno
Tous les auteurs :
Vergès B, Rouland A, Baillot-Rudoni S, Brindisi MC, Duvillard L, Simoneau I, Legris P, Petit JM, Bouillet B
Lien Pubmed
Résumé
Obesity is increasing in patients with type 2 diabetes (T2D). A possible reduced association between fructosamine and HbA1c in obese individuals has been previously discussed, but this has never been specifically evaluated in T2D and the potential influence of body fat mass and fat distribution has never been studied. We studied 112 T2D patients with assessment of fat mass, liver fat and fat distribution. Patients with BMI above the median (34.9 kg/m ), versus BMI below the median, had a correlation coefficient between fructosamine and HbA1c significantly reduced (r=0.358 vs. r=0.765). In the whole population, fructosamine was correlated negatively with BMI and fat mass. In multivariate analysis, fructosamine was associated with HbA1c (positively) and fat mass (negatively) but not with BMI, liver fat or fat distribution. The association between fructosamine and HbA1c is significantly reduced in the most obese T2D patients and this is mostly driven by increased fat mass.
Mots clés
diabetes, fructosamine, obese
Référence
J Diabetes Investig. 2020 Aug 7;: